Anaconda Biomed, a Barcelona, Spain-based pre-clinical stage medical device company focused on the development of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), closed a €15m Series A financing.
Backers included new investors Ysios Capital (Barcelona, Spain), Omega Funds (Boston, MA, USA), Banco Sabadell (Spain) as well as current investor Innogest Capital (Milan, Italy).
Founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, Anaconda Biomed is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
The company intends to use the funds to advance the development of its solution.
In conjunction with the financing, Josep L. Sanfeliu, General Partner at Ysios Capital, and Claudio Nessi, Managing Director at Omega Funds, will join Anaconda Biomed’s Board of Directors. Giovanni Leo, will continue to represent Innogest Capital in the Board.